用于治疗动脉导管未闭的布洛芬赖氨酸盐（诺布洛芬）
Ibuprofen lysine (NeoProfen) for the treatment of patent ductus arteriosus.
作者信息
Poon Grace
机构信息
Department of Pharmacy Services, Baylor University Medical Center, Dallas, Texas.
出版信息
Proc (Bayl Univ Med Cent). 2007 Jan;20(1):83-5. doi: 10.1080/08998280.2007.11928244.
Patent ductus arteriosus (PDA) affects approximately 31% of infants whose birth weight is between 501 and 1500 g. The ductus arteriosus is a blood vessel that allows blood to bypass the pulmonary vasculature in utero. Oxygen delivery and elimination of prostaglandins are essential for the closure of the ductus after birth. For years, indomethacin has been the drug of choice for the treatment of PDA in the USA. Undesirable adverse effects prompted researchers to seek alternative agents. In April 2006, the US Food and Drug Administration approved the use of ibuprofen lysine (NeoProfen) for closure of clinically significant PDA in premature neonates. Ibuprofen's mechanism of action for closure of PDA is believed to be through the inhibition of prostaglandins. Clinical studies have shown ibuprofen to be as effective as indomethacin with fewer adverse effects.
动脉导管未闭（PDA）影响着出生体重在501至1500克之间约31%的婴儿。动脉导管是一条使血液在子宫内绕过肺血管系统的血管。出生后，氧气输送和前列腺素的消除对于动脉导管的闭合至关重要。多年来，在美国，吲哚美辛一直是治疗PDA的首选药物。不良副作用促使研究人员寻找替代药物。2006年4月，美国食品药品监督管理局批准使用赖氨酸布洛芬（NeoProfen）来闭合早产儿临床上显著的PDA。布洛芬闭合PDA的作用机制据信是通过抑制前列腺素。临床研究表明，布洛芬与吲哚美辛效果相当，但副作用更少。
Zotero 插件